Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020

Alexandra K. Heaney, Jennifer R. Head, Kelly Broen, Karen Click,
John Taylor, John R. Balmes, Jon Zelner, Justin V. Remais

We review the interaction between coronavirus disease (COVID-19) and coccidioidomycosis, a respiratory infection caused by inhalation of *Coccidioides* fungal spores in dust. We examine risk for co-infection among construction and agricultural workers, incarcerated persons, Black and Latino populations, and persons living in high dust areas. We further identify common risk factors for co-infection, including older age, diabetes, immunosuppression, racial or ethnic minority status, and smoking. Because these diseases cause similar symptoms, the COVID-19 pandemic might exacerbate delays in coccidioidomycosis diagnosis, potentially interfering with prompt administration of antifungal therapies. Finally, we examine the clinical implications of co-infection, including severe COVID-19 and reactivation of latent coccidioidomycosis. Physicians should consider coccidioidomycosis as a possible diagnosis when treating patients with respiratory symptoms. Preventive measures such as wearing face masks might mitigate exposure to dust and severe acute respiratory syndrome coronavirus 2, thereby protecting against both infections.

Persons with coronavirus disease (COVID-19) can have a wide range of symptoms, including cough, difficulty breathing, and fatigue (*1*). These symptoms are also common among patients with coccidioidomycosis (*2*), a primarily pulmonary disease caused by inhalation of *Coccidioides*, a soil-dwelling dimorphic fungi. These spores spread through the air, especially through wind erosion in dusty environments and dirt disrupting activities such as digging or construction. *Coccidioides* spores are found in hot and arid environments, including much of the southwestern United States, where coccidioidomycosis incidence has been increasing.

Author affiliations: University of California, Berkeley, California, USA (A.K. Heaney, J.R. Head, K. Click, J. Taylor, J.R. Balmes, J.V. Remais); University of Michigan, Ann Arbor, Michigan, USA (K. Broen, J. Zelner); University of California, San Francisco, California, USA (J.R. Balmes)

Since 2016, California has recorded its highest incidences of coccidioidomycosis (*3*,*4*).

We reviewed epidemiologic and clinical literature on coccidioidomycosis and COVID-19 to identify subpopulations that might be at risk for co-infection and severe disease. We discuss how the COVID-19 pandemic might affect coccidioidomycosis diagnosis, surveillance, and clinical management. We also evaluate evidence that co-infection might contribute to severe COVID-19 or reactivation of latent *Coccidioides* infection. Our study informs healthcare providers, policymakers, and populations in regions to which coccidioidomycosis is endemic on potential interactions between this disease and COVID-19, encouraging protective measures and prompt diagnosis.

Methods

We searched peer-reviewed journals on PubMed, Google Scholar, Scopus, and Web of Science; preprints posted on medRxiv and bioRxiv; and reports from state health departments and correctional agencies for articles on risk factors for infection and disease severity, diagnosis, surveillance, and preventive measures for coccidioidomycosis and COVID-19. We assessed titles and abstracts for relevance to the risk factors, diagnostic issues, and complications of coccidioidomycosis and COVID-19 co-infections. We conducted searches published during April–December 2020 and did not exclude articles on the basis of publication date. We identified other relevant publications by backward citation searching. We analyzed 116 peer-reviewed articles, 4 preprints, and 28 reports.

Possible Risk Factors for Coccidioidomycosis and COVID-19

COVID-19 and coccidioidomycosis share certain risk factors for exposure, potentially increasing the risk for co-infection. In California and Arizona, the 2 states with the highest number of reported coccidioidomycosis cases, substantial overlap exists between

county-level incidence of COVID-19 in 2020 and coccidioidomycosis in 2019 (Figures 1, 2).

Occupational Risks

Certain occupations pose increased risk for coccidioidomycosis. Because soil disruption and dusty environments promote dispersal of *Coccidioides* spores, coccidioidomycosis outbreaks frequently occur among workers in the construction and agricultural sectors (*8,9,10*). Of 47 coccidioidomycosis outbreaks reported during 1940–2015, a total of 25 (53%) were associated with occupational exposure, including 15 (60%) that were related to construction (*11*). An analysis of workers' compensation claims found that the incidence of coccidioidomycosis related to occupational exposure nearly quadrupled in California during 2000–2006, the highest rates seen among construction and agricultural workers (*12*).

Continued in-person work within the construction and agricultural sectors, which are considered essential occupations, also increases risk for COVID-19. In the United States, an estimated 8% of construction workers have had workplace exposure to the causative agent of COVID-19, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), at least monthly, and nearly 60% of the construction labor force has $\geq$1 risk factor for severe COVID-19 (*13, 14*). Agricultural workers might also have heightened risk for COVID-19 because of high workforce turnover, shared transportation, and overcrowded living quarters that are often shared with other workers, multigenerational families, or both (*15–19*).

Incarcerated Populations

Incarcerated persons have a high risk for exposure to *Coccidioides* spores and SARS-CoV-2. Prisons and other facilities, such as immigration detention centers, are often in isolated areas with high environmental dust concentrations that can place inmates at higher risk for *Coccidioides* infection (Appendix, https://wwwnc.cdc.gov/EID/article/27/5/20-4661-App1.pdf). In addition, crowding, unsanitary conditions, and poor ventilation in carceral environments contributes to the rapid spread of communicable respiratory diseases like COVID-19 (*20*). Researchers have documented COVID-19 outbreaks among fire-fighting crews composed of incarcerated persons (*21*); similarly, researchers documented 7 coccidioidomycosis outbreaks among such fire-fighting crews during 2000–2017 (*22*). During 1940–2015, a total of 5 (11%) reported coccidioidomycosis outbreaks were among incarcerated populations (*11*). During 2007–2011, a total of 19% of coccidioidomycosis cases in California

were among incarcerated persons (*23*). More than 25% of California Department of Corrections and Rehabilitation facilities, including Lompoc Prison Complex (Lompoc, CA, USA), where a COVID-19 outbreak infected >1,000 persons (*24*), are in regions with high coccidioidomycosis incidence (*25*).

Researchers have documented several outbreaks of COVID-19 in carceral facilities (Appendix). During January 21–April 21, 2020, a total of 82% of reporting state and territorial health department jurisdictions reported confirmed COVID-19 cases among incarcerated or detained persons (including 4,893 reported

Figure 1. County-level incidence of (A) coronavirus disease (COVID-19) in 2020 and (B) coccidioidomycosis in 2019, California and Arizona. COVID-19 incidence reflects cumulative case count as of August 14, 2020 (*5*). Coccidioidomycosis incidence reflects annual incidence in 2019 (*6,7*). Shading indicates levels of incidence. Brackets indicate inclusive bounds; parentheses indicate exclusive bounds.

Figure 2. Scatterplot of county-level incidence of COVID-19 in 2020 and coccidioidomycosis in 2019, California and Arizona. R2 = 0.259; p<0.01.

cases and 88 deaths) or staff members (including 2,778 reported cases and 15 deaths) (26). COVID-19 outbreaks affecting >1,000 persons have occurred among incarcerated persons and staff working at carceral facilities in states from California to New York (Appendix).

Racial and Ethnic Minorities

Substantial racial and ethnic disparities exist in COVID-19 and coccidioidomycosis infection rates. Persons of Black and Latino heritage are at heightened risk for these infections. In California as of February 2021, Latino persons comprise 39% of the total population but account for 55% of COVID-19 cases (27). In the United States, COVID-19 incidence and death rates in counties with predominantly Black populations are significantly higher than in counties with predominantly white populations (28). In addition, Latino persons comprise 39% of the California population but 47% of its coccidioidomycosis patients; in the same state, non-Hispanic Black persons comprise 6% of the population but 9% of coccidioidomycosis patients (3).

Numerous societal inequities (including racism and discrimination, economic and educational disadvantages, and lack of healthcare access) contribute to higher pathogen exposure and infection rates among Black and Latino populations (29). In the context of the COVID-19 pandemic, social distancing might be more difficult for persons of low socioeconomic status because of their overrepresentation in essential occupations, elevated risk of living in densely populated homes and neighborhoods, and higher numbers of multigenerational households (15–19). For example, 55% of Latino and 48% of Black persons work in essential jobs, compared with 35% of White persons (30). Disparities in coccidioidomycosis rates might also be caused by the disproportionate numbers of Black and Latino persons who are incarcerated or work in occupations with high exposure risk. More than 50% of farm laborers, agricultural workers, and construction workers in California are Latino (31,32). In addition, Black and Latino persons are overrepresented in carceral facilities: in California, Black persons comprise 27% and Latino persons comprise 41% of jail and prison populations (33).

Exposure to Particulate Matter

Persons living in environments with high concentrations of dust, which is a major constituent of particulate matter ≤10 μm or ≤2.5 μm in diameter, might be at elevated risk for infection with *Coccidioides* and SARS-CoV-2 and severe illness from COVID-19. Exposure to particulate matter is a risk factor for illness and death from viral respiratory infections, including COVID-19 (Appendix). Exposure to outdoor particulate air pollution is also associated with *Coccidioides* infection because mineral dust can mobilize airborne spores (34,35). Coccidioidomycosis outbreaks have been linked to dust plumes generated by military exercises, agriculture, construction, archeology excavations, windstorms, and landslides (36–43). For example, in an outbreak affecting 89 persons at a solar farm, persons who reported being in a dust cloud had ≈6 times the odds of symptomatic coccidioidomycosis than those who were not in the dust cloud. Wetting the dirt before soil-disrupting activities, a common practice to reduce dust, decreased the odds of symptomatic infection by 58% (44). Because COVID-19 control measures encourage the use of outdoor spaces, persons might have increased exposures to mineral dust and other air pollutants during the pandemic.

Co-Circulation with SARS-CoV-2 Hampering Coccidioidomycosis Diagnosis

The diagnosis of coccidioidomycosis in areas with community transmission of COVID-19 might be challenging because the diseases cause similar symptoms, which might exacerbate existing delays in coccidioidomycosis diagnosis and treatment. Without antifungal treatment, coccidioidomycosis patients are at risk for severe illness, including disseminated disease, and for death (45). Promptly administering antifungal treatments reduces unnecessary use of antimicrobial drugs

and resolves symptoms more effectively (*45*). In addition, early case management, including assessing risk factors for severity, regular follow-up visits to monitor symptoms, regular testing to check antibody titer levels, and physical therapy, is crucial to mitigating severe disease (*46*).

One reason for the underdiagnosis of coccidioidomycosis is low testing rates. For instance, a study in Tucson, Arizona, estimated that 15%–44% of community-acquired pneumonia cases could be attributed to coccidioidomycosis (*47*), but only 2%–13% of community-acquired pneumonia cases were tested for coccidioidomycosis (*48*). Valdivia et al. (*47*) found that half of patients had >2 clinic visits before being tested for coccidioidomycosis. Low sensitivities of coccidioidomycosis tests might further contribute to delays in diagnosis (Appendix). Given such diagnostic constraints, the median time between seeking healthcare and coccidioidomycosis diagnosis was estimated to be 23 days in Arizona (*49*).

The COVID-19 pandemic might contribute to further delays in coccidioidomycosis diagnosis. Both diseases can cause dry cough, muscle aches, headache, fatigue, and difficulty breathing; however, patients with COVID-19 tend to have a more acute progression of symptoms than those with coccidioidomycosis (*50*; Appendix references *51–54*). Although pulmonary specialists and primary care physicians in regions to which coccidioidomycosis is endemic are probably aware of the diagnosis and treatment of this fungal infection, physicians in other regions might be less familiar with the diagnosis. Attributing coccidioidomycosis symptoms to COVID-19, whether presumed or laboratory-confirmed, might preclude coccidioidomycosis diagnosis in patients with monoinfections or co-infections. In addition, underutilization of healthcare services during the COVID-19 pandemic might result in further delays in the testing and diagnosis of coccidioidomycosis (Appendix reference *55*).

Risk Factors for Severe Disease

Although most cases of coccidioidomycosis or COVID-19 are mild respiratory illnesses, either infection can cause severe disease and death (Appendix). Risk factors associated with severe coccidioidomycosis or COVID-19 often overlap, prompting concerns of elevated death rates associated with co-infections or serial infections. Patients with SARS-CoV-2 and *Coccidioides* co-infection might be at higher risk for severe disease; however, whether synergistic effects might exist requires further data. Overlapping risk factors associated with severe disease caused by coccidioidomycosis or COVID-19 include older age, diabetes

mellitus, immunosuppression, Black/African American ancestry, and smoking (Appendix references *56–70*). Although the long-term pulmonary effects of COVID-19 remain unknown, early data suggest that the virus might cause lung damage (Appendix reference *71*), resulting in elevated long-term risk for severe coccidioidomycosis.

Age

Older persons have heightened risk for severe disease caused by either infection. In the United States, 62% of COVID-19 hospitalizations and 80% of deaths were among patients >65 years of age (Appendix reference *72*). Similarly, older persons, especially those >65 years of age, with coccidioidomycosis have higher risk for severe pulmonary disease. Rates of coccidioidomycosis-associated death increase with age. These trends might be partially explained by the higher prevalence among older adults of preexisting conditions and immunosuppression, which are risk factors for severe COVID-19 and coccidioidomycosis (Appendix references *56–64*).

Diabetes

Diabetes is also associated with severe progression of either disease (Appendix references *56,63–68*). A study of COVID-19 patients found that those with diabetes had a higher risk for severe pneumonia and organ damage (Appendix reference *73*). The study also showed that patients with diabetes were more susceptible to a SARS-CoV-2–induced cytokine storm, which can cause rapid deterioration and death (Appendix reference *73*). In addition, patients with diabetes are more likely to have relapsing coccidioidomycosis (risk ratio [RR] 3.39, 95% CI 1.65–6.46) or cavitary lung disease (RR 2.94, 95% CI 1.63–4.90) than those without diabetes (Appendix reference *74*). Furthermore, among coccidioidomycosis patients with diabetes, those with higher serum glucose levels are more likely to have disseminated coccidioidomycosis, the most severe form of the disease, than those with lower levels (Appendix reference *74*). The exact mechanisms through which diabetes influences the progression of coccidioidomycosis and COVID-19 are not well understood but might be related to impaired innate and adaptive cellular immunity (especially T-cell function) or the effects of a hyperglycemic environment on microorganism virulence (Appendix reference *75*).

Immunosuppression

Although immunosuppressive steroids such as dexamethasone have reduced inflammatory lung

damage in patients with severe COVID-19 (Appendix reference *76*), emerging evidence suggests that persons with a history of prolonged immunosuppression might be at higher risk for severe COVID-19. A study of 17 million adults in the United Kingdom found higher risks for death among COVID-19 patients who have hematologic malignancies, who are taking immunosuppressant drugs for organ transplants, or who have other causes of immunosuppression (Appendix reference *77*). Immunosuppressed patients with cancer or solid organ transplants might be at higher risk for severe COVID-19 (Appendix reference *78*). Coccidioidomycosis patients with suppressed immune responses, such as patients with hematologic malignancies, HIV, or organ transplants, also have higher risk for disseminated disease (Appendix references *61–63*).

Black/African American Ancestry
Black persons have higher rates of severe COVID-19 and disseminated coccidioidomycosis than do White persons. Growing evidence indicates higher risk for severe COVID-19–associated disease and death among Black than White persons living in the United States (Appendix). A study of coccidioidomycosis in military personnel found dissemination rates to be 10 times higher among Black than White persons (Appendix reference *79*). Similarly, a study in Kern County, California, found that patients with disseminated coccidioidomycosis were 4.6 times more likely to be Black than patients with mild disease (Appendix reference *56*). The observed racial and ethnic disparities in severe COVID-19 and coccidioidomycosis are probably driven by structural inequities that systematically disadvantage persons of color in the forms of reduced healthcare access and exposure to environmental stressors that increase risk for conditions such as diabetes, obesity, and hypertension, which are associated with severe disease (*29*). For coccidioidomycosis, whether any biological basis for this association exists is unclear but might be related to immunogenic differences in T-cell function (Appendix references *56,69,70*).

Smoking
Recent history of cigarette smoking has been linked to higher risk for severe disease from either infection. A systematic review and meta-analysis found that smokers with COVID-19 were significantly more likely (RR 2.4, 95% CI 1.43–4.04) to be admitted to an intensive care unit, need mechanical ventilation, or die compared with nonsmokers (Appendix reference *80*). A case–control study in Kern County found that patients with severe or disseminated coccidioidomycosis were more likely to have smoked cigarettes in the previous 6 months compared with patients with mild coccidioidomycosis (Appendix reference *56*).

Possible Effects of Co-Infection on Disease Progression

Severe COVID-19
Underlying respiratory illness is a major risk factor for severe COVID-19 (Appendix references *60,64*). The Centers for Disease Control and Prevention reported that among COVID-19 patients in the United States with available data on concurrent conditions, 9.2% had a chronic lung disease such as chronic obstructive pulmonary disease, asthma, or emphysema; chronic lung disease was the most common concurrent condition after diabetes (Appendix reference *81*). The prevalence of chronic lung disease is higher among hospitalized patients (15%) and highest among patients in the intensive care unit (21%) (Appendix reference *81*). Several studies of COVID-19 patients in China have also shown elevated rates of death and severe disease among those with underlying chronic respiratory conditions (Appendix references *64,82,83*). Acute coccidioidomycosis is often self-limiting, but ≈3%–5% of patients have a chronic pulmonary form of the illness (Appendix references *84,85*). The evidence that chronic lung disease increases risk for severe COVID-19 suggests that patients with chronic pulmonary coccidioidomycosis might be predisposed to severe COVID-19.

Coccidioidomycosis Reactivation
Infection with COVID-19 might reactivate disease in a coccidioidomycosis patient whose illness has progressed to a chronic but inactive state. After an initial *Coccidioides* infection resolves, the fungus can remain in the lungs in a latent state and become reactivated under certain conditions (Appendix references *86–93*). Coccidioidomycosis reactivation has been reported among pregnant women, especially those who previously had disseminated coccidioidomycosis (Appendix reference *94*). Patients with organ transplants, which usually require immunosuppressive medications, also have higher rates of coccidioidomycosis reactivation (Appendix references *87–92*). SARS-CoV-2 infection has been associated with immune dysregulation, including lymphopenia (Appendix reference *95*), which might lower the host's ability to regulate *Coccidioides* infection (Appendix reference *96*). Although no studies have reported coccidioidomycosis reactivation in COVID-19 patients

as of February 2021, emerging evidence suggests that COVID-19 infection might accelerate the reactivation of latent tuberculosis (L. Pathak, unpub. data, https://www.biorxiv.org/content/10.1101/2020.05.06.077883v2). In addition, dexamethasone, a medication recommended for patients with severe COVID-19, increases the risk for severe coccidioidomycosis (Appendix references *97,98*).

Areas for Future Research

Cloth Masks
Although cloth masks are a critical control method for COVID-19 (Appendix), studies have not examined the efficacy of cloth masks for filtering *Coccidioides* arthroconidia. At 2–5 µm in diameter, *Coccidioides* arthroconidia are substantially larger than SARS-CoV-2; this size difference might lead to differing levels of filtration effectiveness (Appendix references *99,100*). One study found that cloth masks containing tightly woven cottons can filter 98% of particles in the 300 nm–6 µm range (Appendix reference *101*), yet such results are difficult to extrapolate to specific particles such as *Coccidioides* arthroconidia (Appendix reference *102*). It is also difficult to extrapolate results to other cloth masks, which vary widely in their filtration properties. Furthermore, leakage from improperly fitting masks can reduce efficacy of particle filtration by up to 50% (Appendix reference *101*). The effects of leakage on disease prevention might differ on the basis of infectious dose; although a single *Coccidioides* spore might confer infection, the infectious dose of SARS-CoV-2 is probably higher. California therefore requires employers with worksites in regions to which coccidioidomycosis is endemic to provide respiratory protection filters rated at least N95 to workers if dust cannot be controlled; no mask recommendation exists for the general public (Appendix reference *103*).

Climate
Transmission of SARS-CoV-2 and *Coccidioides* spores might be influenced by climatic conditions, such as temperature and humidity, that can affect pathogen survival and transport. For example, high humidity can suppress aerosol transmission of respiratory pathogens such as influenza and respiratory syncytial virus (Appendix references *104–110*). Early research in Wuhan, China, suggested that SARS-CoV-2 might be transmitted more efficiently in less humid environments (Appendix references *111–113*; W. Luo, unpub. data, https://www.medrxiv.org/content/10.1101/2020.02.12.20022467v1). Although the influence of temperature and other climatic conditions on transmission and

seasonality of SARS-CoV-2 currently might be outweighed by the large size of the susceptible population, the introduction of a vaccine could result in patterns of population immunity that enable climate to play a larger moderating role (Appendix reference *114*). Because relative humidity plays a major role in regulating atmospheric dust concentrations, high atmospheric moisture can limit the dispersal of *Coccidioides* spores, potentially suppressing coccidioidomycosis transmission. For example, under wind conditions strong enough to mobilize dust, increases in relative humidity were associated with decreasing atmospheric dust concentrations (Appendix reference *115*).

Disparities in Surveillance
The extent of socioeconomic, demographic, racial, and other disparities in COVID-19 and coccidioidomycosis is probably greater than reflected in administrative data sources. For example, analyses from hard-hit regions have indicated that high rates of excess death probably reflect a large burden of unreported SARS-CoV-2 infection (Appendix reference *116*; J. Felix-Cardoso, unpub. data, https://www.medrxiv.org/content/10.1101/2020.04.28.20083147v1). Although testing coverage for SARS-CoV-2 is increasing, infections will probably continue to be undercounted in certain regions and populations because of factors such as disparate healthcare access, reagent shortages, and varied willingness to get tested. Undocumented or migrant farmworkers at high risk for exposure to *Coccidioides* spores are mostly uninsured, ineligible for healthcare benefits, or unable to afford healthcare (Appendix reference *117,118*). The disparities seen in rates of illness and death caused by COVID-19 and coccidioidomycosis might have many contributing factors, including barriers to affordable, high-quality, and accessible healthcare; occupational exposures; mass incarceration; residential segregation; discrimination; and differential rates of concurrent conditions. Understanding these disparities is critical for attracting the attention and resources needed to remedy inequities in exposures, care-seeking, and illness and death caused by coccidioidomycosis and COVID-19.

Conclusions
Public health professionals, healthcare providers, and populations in areas to which coccidioidomycosis is endemic should be aware of the overlap in risk factors for coccidioidomycosis and COVID-19. Because prompt diagnosis is critical for effective management of coccidioidomycosis and the COVID-19 pandemic might exacerbate existing delays,

healthcare professionals should know how to identify these diseases and potential co-infection. Agricultural and construction workers, firefighters, Black and Latino persons, persons with diabetes, elderly persons, incarcerated persons, and migrant or undocumented farmworkers might be at increased risk for coccidioidomycosis and COVID-19. Employers and public health officials should mitigate exposure to dust and SARS-CoV-2 by promoting the use of face masks and social distancing practices.

Dr. Heaney is a postdoctoral scholar at the University of California, Berkeley, California, USA. Her research interests include the epidemiology and environmental determinants of infectious diseases.

References

1. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382:2372–4. https://doi.org/10.1056/NEJMc2010419

2. Blair JE, Chang YHH, Cheng MR, Vaszar LT, Vikram HR, Orenstein R, et al. Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerg Infect Dis. 2014;20:983–90. https://doi.org/10.3201/eid2006.131842

3. California Department of Public Health. Epidemiological summary of coccidioidomycosis in California, 2018. 2019 [cited 2020 May 18]. https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CocciEpiSummary2018.pdf

4. Centers for Disease Control and Prevention. Valley fever (coccidiomycosis) statistics. 2020 [cited 2020 May 14]. https://www.cdc.gov/fungal/diseases/coccidioidomycosis/statistics.html

5. USAFacts. US coronavirus cases and deaths by state. 2020 [cited 2020 May 21]. https://usafacts.org/visualizations/coronavirus-covid-19-spread-map

6. California Department of Public Health. Coccidioidomycosis in California provisional monthly report: January–April 2020. 2020 [cited 2020 May 28]. https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CocciinCAProvisionalMonthlyReport.pdf

7. Arizona Department of Health Services. Valley fever 2019 annual report. 2021 [cited 2021 Feb 24]. https://www.azdhs.gov/documents/preparedness/epidemiology-disease-control/valley-fever/reports/valley-fever-2019.pdf

8. Levan NE, Huntington RW. Primary cutaneous coccidioidomycosis in agricultural workers. Arch Dermatol. 1965;92:215–20. https://doi.org/10.1001/archderm.1965.01600150005001

9. Schmelzer LL, Tabershaw IR. Exposure factors in occupational coccidioidomycosis. Am J Public Health Nations Health. 1968;58:107–13. https://doi.org/10.2105/AJPH.58.1.107

10. Johnson WM. Occupational factors in coccidioidomycosis. J Occup Med. 1981;23:367–74.

11. Freedman M, Jackson BR, McCotter O, Benedict K. Coccidioidomycosis outbreaks, United States and worldwide, 1940–2015. Emerg Infect Dis. 2018;24:417–23. https://doi.org/10.3201/eid2403.170623

12. Das R, McNary J, Fitzsimmons K, Dobraca D, Cummings K, Mohle-Boetani J, et al. Occupational coccidioidomycosis in California: outbreak investigation, respirator recommendations, and surveillance findings. J Occup Environ Med. 2012;54:564–71. https://doi.org/10.1097/JOM.0b013e3182480556

13. Baker MG, Peckham TK, Seixas NS. Estimating the burden of United States workers exposed to infection or disease: a key factor in containing risk of COVID-19 infection. PLoS One. 2020;15:e0232452. https://doi.org/10.1371/journal.pone.0232452

14. Brown S, Brooks R, Dong XS. Coronavirus and health disparities in construction. The Center for Construction Research and Training. 2020 [cited 2020 Oct 16]. https://www.cpwr.com/wp-content/uploads/publications/DataBulletin-May2020.pdf

15. Acs G, Loprest PJ. Job differences by race and ethnicity in the low-skill job market. The Urban Institute. 2009 [cited 2020 Jun 15]. https://www.urban.org/sites/default/files/publication/30146/411841-Job-Differences-by-Race-and-Ethnicity-in-the-Low-Skill-Job-Market.PDF

16. Murray CJL, Kulkarni SC, Michaud C, Tomijima N, Bulzacchelli MT, Iandiorio TJ, et al. Eight Americas: investigating mortality disparities across races, counties, and race-counties in the United States [Erratum in: PLoS Med. 2006 Dec;3:e545]. PLoS Med. 2006;3:e260. https://doi.org/10.1371/journal.pmed.0030260

17. Centers for Disease Control and Prevention. Communities, schools, workplaces, and events. 2020 [cited 2020 Oct 16]. https://www.cdc.gov/coronavirus/2019-ncov/community/guidance-agricultural-workers.html

18. Arcury TA, Weir M, Chen H, Summers P, Pelletier LE, Galván L, et al. Migrant farmworker housing regulation violations in North Carolina. Am J Ind Med. 2012;55:191–204. https://doi.org/10.1002/ajim.22011

19. Quandt SA, Brooke C, Fagan K, Howe A, Thornburg TK, McCurdy SA. Farmworker housing in the United States and its impact on health. New Solut. 2015;25:263–86. https://doi.org/10.1177/1048291115601053

20. Simpson PL, Simpson M, Adily A, Grant L, Butler T. Prison cell spatial density and infectious and communicable diseases: a systematic review [Erratum in: BMJ Open. 2020;10: e026806corr1]. BMJ Open. 2019;9:e026806. https://doi.org/10.1136/bmjopen-2018-026806

21. Sabalow R, Pohl J. California severely short on firefighting crews after COVID-19 lockdown at prison camps. The Sacramento Bee. 2020 [cited 2020 Aug 18]. https://www.sacbee.com/news/california/fires/article243977827.html

22. Lucas KD, Wheeler C, Mohle-Boetani JC. Coccidioidomycosis outbreaks among inmate wildland firefighters in California. Proceedings of the 63rd Coccidioidomycosis Study Group Annual Meeting; 2019 Apr 5–6. Sacramento, CA, USA.

23. MacLean M. Epidemiology of coccidioidomycosis—15 California counties, 2007–2011. 2014 [cited 2020 May 28]. https://www.vfce.arizona.edu/sites/vfce/files/the_epidemiology_of_coccidioidomycosis_collaborative_county_report.pdf

24. The New York Times. Coronavirus in the U.S.: latest map and case count. 2020 [cited 2020 May 28]. https://www.

nytimes.com/interactive/2020/us/coronavirus-us-cases. html?auth=login-email&login=email

25. Prison Law Office. Valley fever and CDCR housing. 2019 [cited 2020 May 28]. https://prisonlaw.com/wp-content/ uploads/2019/04/Valley-Fever-info-April-2019.pdf

26. Wallace M, Hagan L, Curran KG, Williams SP, Handanagic S, Bjork A, et al. COVID-19 in correctional and detention facilities—United States, February–April 2020. MMWR Morb Mortal Wkly Rep. 2020;69:587–90. https://doi.org/10.15585/mmwr.mm6919e1

27. California Department of Public Health. COVID-19 race and ethnicity data. 2020 [cited 2020 Jun 15]. https://www.cdph. ca.gov/Programs/CID/DCDC/Pages/COVID-19/ Race-Ethnicity.aspx

28. Moore JT, Ricaldi JN, Rose CE, Fuld J, Parise M, Kang GJ, et al. Disparities in incidence of COVID-19 among underrepresented racial/ethnic groups in counties identified as hotspots during June 5–18, 2020—22 states, February– June 2020. MMWR Morb Mortal Wkly Rep. 2020;69:1122–6. https://dx.doi.org/10.15585/mmwr.mm6933

29. Zelner J, Trangucci R, Naraharisetti R, Cao A, Malosh R, Broen K, et al. Racial disparities in COVID-19 mortality are driven by unequal infection risks. Clin Infect Dis. 2020;72:e88–95. https://doi.org/10.1093/cid/ciaa1723

30. Thomason S, Bernhardt A. Front-line essential jobs in California: a profile of job and worker characteristics. UC Berkeley Labor Center. 2020 [cited 2020 Aug 18]. https://laborcenter.berkeley.edu/front-line-essential-jobs- in-california-a-profile-of-job-and-worker-characteristics/

31. United States Department of Agriculture. Farm labor. 2020 [cited 2020 Jun 15]. https://www.ers.usda.gov/topics/ farm-economy/farm-labor/#demographic

32. United States Census Bureau. Five-year public use microdata sample (PUMS), 2014–2018. 2020 [cited 2020 Jun 15]. https://www.census.gov/programs-surveys/acs/ technical-documentation/pums/documentation.html

33. United States Census Bureau. 2010 census summary file 1. 2016 [cited 2020 Jun 5]. https://www.census.gov/data/ datasets/2010/dec/summary-file-1.html

34. Chow NA, Griffin DW, Barker BM, Loparev VN, Litvintseva AP. Molecular detection of airborne *Coccidioides* in Tucson, Arizona. Med Mycol. 2016;54:584–92. https://doi.org/10.1093/mmy/myw022

35. Pappagianis D, Einstein H. Tempest from Tehachapi takes toll or *Coccidioides* conveyed aloft and afar. West J Med. 1978; 129:527–30.

36. Das R, McNary J, Fitzsimmons K, Dobraca D, Cummings K, Mohle-Boetani J, et al. Occupational coccidioidomycosis in California: outbreak investigation, respirator recommendations, and surveillance findings. J Occup Environ Med. 2012;54:564–71. https://doi.org/10.1097/ JOM.0b013e3182480556

37. Cummings KC, McDowell A, Wheeler C, McNary J, Das R, Vugia DJ, et al. Point-source outbreak of coccidioidomycosis in construction workers. Epidemiol Infect. 2010;138:507–11. https://doi.org/10.1017/S0950268809990999

38. Petersen LR, Marshall SL, Barton C, Hajjeh RA, Lindsley MD, Warnock DW, et al. Coccidioidomycosis among workers at an archeological site, northeastern Utah. Emerg Infect Dis. 2004;10:637–42. https://doi.org/10.3201/eid1004.030446

39. Standaert SM, Schaffner W, Galgiani JN, Pinner RW, Kaufman L, Durry E, et al. Coccidioidomycosis among

visitors to a *Coccidioides immitis*–endemic area: an outbreak in a military reserve unit. J Infect Dis. 1995;171:1672–5. https://doi.org/10.1093/infdis/171.6.1672

40. Wilken JA, Sondermeyer G, Shusterman D, McNary J, Vugia DJ, McDowell A, et al. Coccidioidomycosis among workers constructing solar power farms, California, USA, 2011–2014. Emerg Infect Dis. 2015;21:1997–2005. https://doi.org/10.3201/eid2111.150129

41. de Perio MA, Materna BL, Sondermeyer Cooksey GL, Vugia DJ, Su CP, Luckhaupt SE, et al. Occupational coccidioidomycosis surveillance and recent outbreaks in California. Med Mycol. 2019;57:S41–5. https://doi.org/ 10.1093/mmy/myy031

42. Gorris ME, Cat LA, Zender CS, Treseder KK, Randerson JT. Coccidioidomycosis dynamics in relation to climate in the southwestern United States. Geohealth. 2018;2:6–24. https://doi.org/10.1002/2017GH000095

43. Schneider E, Hajjeh RA, Spiegel RA, Jibson RW, Harp EL, Marshall GA, et al. A coccidioidomycosis outbreak following the Northridge, Calif, earthquake. JAMA. 1997;277:904–8. https://doi.org/10.1001/jama.1997. 03540350054033

44. Sondermeyer Cooksey GL, Wilken JA, McNary J, Gilliss D, Shusterman D, Materna BL, et al. Dust exposure and coccidioidomycosis prevention among solar power farm construction workers in California. Am J Public Health. 2017;107:1296–303. https://doi.org/10.2105/ AJPH.2017.303820

45. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Johnson RH, Stevens DA, et al. Coccidioidomycosis. Clin Infect Dis. 2005;41:1217–23. https://doi.org/10.1086/496991

46. Galgiani JN, Blair JE, Ampel NM, Thompson GR. Treatment for early, uncomplicated coccidioidomycosis: what is success? Clin Infect Dis. 2020;70:2008–12. https://doi.org/10.1093/cid/ciz933

47. Valdivia L, Nix D, Wright M, Lindberg E, Fagan T, Lieberman D, et al. Coccidioidomycosis as a common cause of community-acquired pneumonia. Emerg Infect Dis. 2006;12:958–62. https://doi.org/10.3201/eid1206.060028

48. Chang DC, Anderson S, Wannemuehler K, Engelthaler DM, Erhart L, Sunenshine RH, et al. Testing for coccidioidomycosis among patients with community-acquired pneumonia. Emerg Infect Dis. 2008;14:1053–9. https://doi.org/10.3201/ eid1407.070832

49. Tsang CA, Anderson SM, Imholte SB, Erhart LM, Chen S, Park BJ, et al. Enhanced surveillance of coccidioidomycosis, Arizona, USA, 2007–2008. Emerg Infect Dis. 2010;16:1738–44. https://doi.org/10.3201/eid1611.100475

50. Fu L, Wang B, Yuan T, Chen X, Ao Y, Fitzpatrick T, et al. Clinical characteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta- analysis. J Infect. 2020;80:656–65. https://doi.org/10.1016/ j.jinf.2020.03.041

51. Goyal P, Choi JJ, Pinheiro LC, Schenck EJ, Chen R, Jabri A, et al. Clinical characteristics of Covid-19 in New York City. N Engl J Med. 2020;382:2372–4. https://doi.org/10.1056/ NEJMc2010419

Coccidioidomycosis and COVID-19 Co-Infection, United States, 2020

Appendix

Appendix Results

Coronavirus Disease Among Construction and Agricultural Workers

Construction, agriculture, and wildland firefighting are considered essential occupations under coronavirus disease (COVID-19) shelter-in-place guidelines for California and Arizona (*119*). Continued in-person work in these sectors poses challenges to maintaining physical distance and limiting contacts, resulting in higher risks for infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (*120,121*). For instance, ≈8% of persons in construction occupations across the United States are exposed to SARS-CoV-2 $\geq$1 time a month (*121*), and nearly 60% of the construction labor force in the United States has $\geq$1 factor (>65 years of age or preexisting medical condition) that is associated with higher risk for severe illness from COVID-19 (*122*). Outbreaks of COVID-19 have been documented at multiple construction sites across the United States (*123–126*), including a cluster of 10 confirmed cases and >30 exposures at a construction site in Santa Clara, California (*126*), and 75 confirmed cases among a construction crew in Salt Lake City, Utah (*125*).

Agricultural workers might also have heightened risk for COVID-19 because of high workforce mobility, shared transportation, and overcrowded living quarters, often shared with other workers, multigenerational families, or both (*127–129*). One study estimated that >133,000 agricultural workers across the United States had tested positive for COVID-19 by September 1, 2020 (*130*), and media reports have documented clusters of COVID-19 at farms in >17 states (*131*). Some of the largest COVID-19 clusters among agricultural workers have been documented in California counties to which coccidioidomycosis is endemic, including Merced (1 cluster involving 392 COVID-19 cases and 8 deaths) (*132*), Ventura (3 clusters with 201, 35, and 28 COVID-19 cases) (*133–135*), and Monterey (1 cluster involving 247 COVID-19 cases) (*136*).

COVID-19 within Carceral Facilities

Crowding, unsanitary conditions, and poor ventilation in prison environments is known to contribute to rapid spread of communicable respiratory diseases (*137*), including influenza and tuberculosis (*138–141*). As the introduction of 1 case of influenza into a prison setting has been found to be sufficient to spark a large outbreak (*139*), concerns surrounding the spread of COVID-19 among detainees and staff members at correctional facilities are high (*142,143*). During January 21–April 21, 2020, 82% (32/37) of reporting state and territorial health department jurisdictions reported confirmed COVID-19 cases among incarcerated or detained persons or staff members (*144*). As of April 21, 2020, a total of 4,893 cases and 88 deaths among incarcerated and detained persons and 2,778 cases and 15 deaths among staff members in these 37 jurisdictions have been reported to the Centers for Disease Control and Prevention (CDC) (*144*). Large COVID-19 outbreaks have been documented among incarcerated persons and staff working at carceral facilities in Lompoc Prison Complex in Lompoc, California (n = 1,111 cases) (*145*), San Quentin State Prison in California (n = 2,221) (*145*), Rikers Island in New York, New York (n = 1,711) (*146*), the Cook County Jail in Chicago, Illinois (n = 1,040) (*147*), and Marion Correctional Institution in Marion, Ohio (n = 2,168) (*148*). COVID-19 outbreaks have also been documented at training camps for fire-fighting crews comprising incarcerated persons in northern California (*149*).

Coccidioidomycosis within Carceral Facilities

In 1 review, 5/47 (11%) reported coccidioidomycosis outbreaks were among incarcerated populations (*150*). During 2007–2011, 19% of coccidioidomycosis cases in California were among incarcerated persons (*151*). Over a quarter of California Department of Corrections and Rehabilitation facilities, including Lompoc Prison Complex, where a COVID-19 outbreak of >1,000 cases occurred (*147*), are in regions with high coccidioidomycosis incidence (*152*). One study showed that *Coccidioides* spores were detected in 15% of air samples taken outside Avenal State Prison (*153*) in Kings County, California, where the incidence of coccidioidomycosis during 2007–2011 was nearly 6 times higher than that of the nearby city (2,195 vs. 411 cases/100,000 population) and 14 times higher than the surrounding county (155 cases/100,000) (*151*). Pleasant Valley State Prison in Fresno County, CA, recorded an incidence of 3,323 cases/100,000 persons in 2005, or 415 times higher than the incidence of the surrounding county (8 cases/100,000 persons) (*154*). Other prisons in endemic areas, such as those in 3 Kern County

cities of Delano, Wasco, and Taft, have reported incidence rates ≈2 times that of the surrounding county (*151*).

COVID-19 and Particulate Matter

Persons living in environments with high concentrations of dust, which is an important constituent of particulate matter with diameter ≤10 μm (PM10) or ≤2.5 μm (PM2.5), might be at elevated risk for infection with *Coccidioides* and SARS-CoV-2, as well as increased severity of COVID-19 infection. Exposure to PM10 and PM2.5 has been recognized as a risk factor for disease and death from viral respiratory infection (*155*), including severe acute respiratory syndrome coronavirus (*156*). Macrophages laden with fine particles might have reduced ability to induce immune responses leading to increased disease severity (*157,158*), and PM2.5 has been shown to exacerbate underlying health conditions such as diabetes and chronic lung disease (*159*), that can complicate the course of viral respiratory infections. Evidence from several countries suggests that both acute and chronic exposure to fine particulate matter is associated with increased COVID-19 disease and death (*160*). For example, 1 study found that a 1 μg/m^3 increase in long-term exposure to PM2.5 was associated with an 8% increase in the COVID-19 death rate in counties across the United States (*161*). In a study of 120 cities in China, elevated particulate matter in the previous 2 weeks was associated with a 2.2% increase in daily confirmed COVID-19 cases (*162*). In Italy, the number of days in the previous 4 years that had exceeded regulatory limits for atmospheric pollutants such as PM2.5 and PM10 was significantly associated with increased COVID-19 cases (*163*).

Diagnostic Tests for Coccidioidomycosis

Laboratory confirmation is necessary to distinguish coccidioidomycosis from other conditions (*45*), and serologic detection of anticoccidiodal antibodies is the most common method to diagnose coccidioidomycosis infection, partly because of the low sensitivity (≈46%–67%) of culture-based methods in respiratory samples (*164–166*). Newer serologic assays for IgM antibodies have sensitivities ranging from 68% to 88% (*167,168*), but IgM antibodies are not typically detectable until 7–21 days after symptom onset, and IgG antibodies even later (*164,165,169*). As a result, a coccidioidomycosis diagnosis might occur ≥1 month after symptom onset. The high rate of false negatives (≤32%) in coccidioidomycosis testing (*165*) further complicate the situation. Given the low sensitivities, experts recommend repeated testing if the original test is negative and symptoms persist (*98,170*). COVID-19 might make patients less

likely to return to their healthcare providers for a second test due to fear of exposure to SARS-CoV-2 in medical facilities.

Prevalence of Severe Disease in COVID-19 and Coccidioidomycosis Patients

Among coccidioidomycosis patients, ≈5% develop severe chronic infections, and 1% progress to disseminated disease in which the infection spreads beyond the pulmonary system (*68*). Disseminated disease can lead to meningitis, bone and skin lesions, swollen joints, hospitalization, and death (*56*). An estimated 80% of COVID-19 cases are mild (no or mild pneumonia), 15% are severe (severe pneumonia and respiratory distress), and 5% are critical (respiratory failure, septic shock, organ dysfunction/failure) (*82*).

COVID-19 Risk among Black/African American Persons

Growing evidence points toward higher risk for severe disease and death from COVID-19 among Black persons living in the United States. Compared with White persons, the age-adjusted COVID-19 death rate on August 4, 2020 was 3.7 times higher among those who identify as Black (80.4 deaths/100,000 persons vs. 35.9 deaths/100,000 persons) (*171*). This trend is reflected across coccidioidomycosis endemic states, such as California and Arizona. In Arizona, the age-adjusted death rate from COVID-19 among Black populations is 2.1 times higher than among White populations. In California, the age-adjusted death rate from COVID-19 among Black populations is 3.0 times higher than among White populations (*171*).

COVID-19 and Cloth Masks

The CDC has recommended that all Americans wear cloth face coverings in public settings to reduce transmission of SARS-CoV-2 (*99*). Although cloth masks are inadequate for filtering out the SARS-CoV-2 virus (which is only 70–90 nm in size) and do not protect the wearer from inhaling viral particles (*172*), masks can protect wearers from virus suspended in large droplets and can prevent wearers from spreading droplets by coughing, sneezing, or breathing. Mask use is recommended for the entire population because persons are believed to be most infectious before the onset of COVID-19 symptoms (*173*). Models suggest that if 80% of the American population wore cloth face masks consistently, COVID-19 transmission would decrease significantly, even if lock-down restrictions were loosened (D. Kai, unpub. data, https://arxiv.org/abs/2004.13553v1), but 1 national survey found that only 60% of respondents follow CDC mask recommendations (*174*).

References

52. Blair JE, Chang Y-HH, Cheng M-R, Vaszar LT, Vikram HR, Orenstein R, et al. Characteristics of patients with mild to moderate primary pulmonary coccidioidomycosis. Emerg Infect Dis. 2014;20:983–90. PubMed https://doi.org/10.3201/eid2006.131842

53. Shah AS, Heidari A, Civelli VF, Sharma R, Clark CS, Munoz AD, et al. The coincidence of 2 epidemics, coccidioidomycosis and SARS-CoV-2: a case report. J Investig Med High Impact Case Rep. 2020;8:2324709620930540. PubMed https://doi.org/10.1177/2324709620930540

54. Benedict K, Kobayashi M, Garg S, Chiller T, Jackson BR. Symptoms in blastomycosis, coccidioidomycosis, and histoplasmosis versus other respiratory illnesses in commercially insured adult outpatients—United States, 2016–2017. Clin Infect Dis. 2020;ciaa1554. https://doi.org/10.1093/cid/ciaa1554

55. De Filippo O, D'Ascenzo F, Angelini F, Bocchino PP, Conrotto F, Saglietto A, et al. Reduced rate of hospital admissions for ACS during Covid-19 outbreak in Northern Italy. N Engl J Med. 2020;383:88–9. PubMed https://www.nejm.org/doi/10.1056/NEJMc2009166

56. Rosenstein NE, Emery KW, Werner SB, Kao A, Johnson R, Rogers D, et al. Risk factors for severe pulmonary and disseminated coccidioidomycosis: Kern County, California, 1995–1996. Clin Infect Dis. 2001;32:708–14. PubMed https://doi.org/10.1086/319203

57. Sondermeyer Cooksey GL, Kamali A, Vugia D, Jain S. 1708. Epidemiology of coccidioidomycosis-associated hospitalizations and in-hospital deaths, California, 2000–2017. Open Forum Infect Dis. 2019;6:S626. https://doi.org/10.1093/ofid/ofz360.2512

58. Sondermeyer GL, Lee LA, Gilliss D, Vugia DJ. Coccidioidomycosis-associated deaths in California, 2000–2013. Public Health Rep. 2016;131:531–5. PubMed https://doi.org/10.1177/0033354916662210

59. CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343–6. PubMed https://doi.org/10.15585/mmwr.mm6912e2

60. Shi Y, Yu X, Zhao H, Wang H, Zhao R, Sheng J. Host susceptibility to severe COVID-19 and establishment of a host risk score: findings of 487 cases outside Wuhan. Crit Care. 2020;24:108. PubMed https://doi.org/10.1186/s13054-020-2833-7

61. Masannat FY, Ampel NM. Coccidioidomycosis in patients with HIV-1 infection in the era of potent antiretroviral therapy. Clin Infect Dis. 2010;50:1–7. PubMed https://doi.org/10.1086/648719

62. Blair JE, Smilack JD, Caples SM. Coccidioidomycosis in patients with hematologic malignancies. Arch Intern Med. 2005;165:113–7. PubMed https://doi.org/10.1001/archinte.165.1.113

63. Santelli AC, Blair JE, Roust LR. Coccidioidomycosis in patients with diabetes mellitus. Am J Med. 2006;119:964–9. PubMed https://doi.org/10.1016/j.amjmed.2006.03.033

64. Yang J, Zheng Y, Gou X, Pu K, Chen Z, Guo Q, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–5. https://doi.org/10.1016/j.ijid.2020.03.017

65. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;36:e3319. PubMed https://doi.org/10.1002/dmrr.3319

66. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8:e21. PubMed https://doi.org/10.1016/S2213-2600(20)30116-8

67. Collaborative TO, Williamson E, Walker AJ, Bhaskaran KJ, Bacon S, Bates C, et al. OpenSAFELY: factors associated with COVID-19-related hospital death in the linked electronic health records of 17 million adult NHS patients. Nature. 2020;584:430–6. PubMed https://doi.org/10.1038/s41586-020-2521-4

68. Brown J, Benedict K, Park BJ, Thompson GR III. Coccidioidomycosis: epidemiology. Clin Epidemiol. 2013;5:185–97. PubMed

69. Stewart ER, Thompson GR III. Update on the epidemiology of coccidioidomycosis. Curr Fungal Infect Rep. 2016;10:141–6. https://doi.org/10.1007/s12281-016-0266-1

70. Louie L, Ng S, Hajjeh R, Johnson R, Vugia D, Werner SB, et al. Influence of host genetics on the severity of coccidioidomycosis. Emerg Infect Dis. 1999;5:672–80. PubMed https://doi.org/10.3201/eid0505.990508

71. Salehi S, Reddy S, Gholamrezanezhad A. Long-term pulmonary consequences of coronavirus disease 2019 (COVID-19). J Thorac Imaging. 2020;35:W87–9. PubMed https://doi.org/10.1097/RTI.0000000000000534

72. Bialek S, Boundy E, Bowen V, Chow N, Cohn A, Dowling N, et al.; CDC COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:343–6. https://doi.org/10.15585/mmwr.mm6912e2

73. Guo W, Li M, Dong Y, Zhou H, Zhang Z, Tian C, et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab Res Rev. 2020;e3319. PubMed https://doi.org/10.1002/dmrr.3319

74. Santelli AC, Blair JE, Roust LR. Coccidioidomycosis in patients with diabetes mellitus. Am J Med. 2006;119:964–9. PubMed https://doi.org/10.1016/j.amjmed.2006.03.033

75. Geerlings SE, Hoepelman AI. Immune dysfunction in patients with diabetes mellitus (DM). FEMS Immunol Med Microbiol. 1999;26:259–65. PubMed https://doi.org/10.1111/j.1574-695X.1999.tb01397.x

76. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2020 Jul 27 [Epub ahead of print]. PubMed https://doi.org/10.1056/NEJMoa2021436

77. Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors associated with COVID-19–related death using OpenSAFELY. Nature. 2020;584:430–6. PubMed https://doi.org/10.1038/s41586-020-2521-4

78. Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2020;72:340–50. PubMed https://doi.org/10.1093/cid/ciaa863

79. Smith CE, Beard RR. Varieties of coccidioidal infection in relation to the epidemiology and control of the diseases. Am J Public Health Nations Health. 1946;36:1394–402. PubMed https://doi.org/10.2105/AJPH.36.12.1394

80. Vardavas CI, Nikitara K. COVID-19 and smoking: a systematic review of the evidence. Tob Induc Dis. 2020;18:20. PubMed https://doi.org/10.18332/tid/119324

81. CDC COVID-19 Response Team. Preliminary estimates of the prevalence of selected underlying health conditions among patients with coronavirus disease 2019—United States, February 12–March 28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:382–6.

82. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China. JAMA. 2020;323:1239–42. PubMed https://doi.org/10.1001/jama.2020.2648

83. Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395:1054–62. PubMed https://doi.org/10.1016/S0140-6736(20)30566-3

84. Sarosi GA, Parker JD, Doto IL, Tosh FE. Chronic pulmonary coccidioidomycosis. N Engl J Med. 1970;283:325–9. PubMed https://doi.org/10.1056/NEJM197008132830701

85. Twarog M, Thompson GR III. Coccidioidomycosis: recent updates. Semin Respir Crit Care Med. 2015;36:746–55. PubMed https://doi.org/10.1055/s-0035-1562900

86. Bercovitch RS, Catanzaro A, Schwartz BS, Pappagianis D, Watts DH, Ampel NM. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis. 2011;53:363–8. PubMed https://doi.org/10.1093/cid/cir410

87. Cha JM, Jung S, Bahng HS, Lim CM, Han DJ, Woo JH, et al. Multi-organ failure caused by reactivated coccidioidomycosis without dissemination in a patient with renal transplantation. Respirology. 2000;5:87–90. PubMed https://doi.org/10.1046/j.1440-1843.2000.00232.x

88. Keckich DW, Blair JE, Vikram HR, Seville MT, Kusne S. Reactivation of coccidioidomycosis despite antifungal prophylaxis in solid organ transplant recipients. Transplantation. 2011;92:88–93. PubMed https://doi.org/10.1097/TP.0b013e31821c1df6

89. Vucicevic D, Carey EJ, Blair JE. Coccidioidomycosis in liver transplant recipients in an endemic area. Am J Transplant. 2011;11:111–9. PubMed https://doi.org/10.1111/j.1600-6143.2010.03328.x

90. Mendoza N, Noel P, Blair JE. Diagnosis, treatment, and outcomes of coccidioidomycosis in allogeneic stem cell transplantation. Transpl Infect Dis. 2015;17:380–8. PubMed https://doi.org/10.1111/tid.12372

91. Blair JE. Approach to the solid organ transplant patient with latent infection and disease caused by *Coccidioides* species. Curr Opin Infect Dis. 2008;21:415–20. PubMed https://doi.org/10.1097/QCO.0b013e3283073828

92. Blair JE, Kusne S, Carey EJ, Heilman RL. The prevention of recrudescent coccidioidomycosis after solid organ transplantation. Transplantation. 2007;83:1182–7. PubMed https://doi.org/10.1097/01.tp.0000260143.54103.0d

93. Stockamp NW, Thompson GR III. Coccidioidomycosis. Infect Dis Clin North Am. 2016;30:229–46. PubMed https://doi.org/10.1016/j.idc.2015.10.008

94. Bercovitch RS, Catanzaro A, Schwartz BS, Pappagianis D, Watts DH, Ampel NM. Coccidioidomycosis during pregnancy: a review and recommendations for management. Clin Infect Dis. 2011;53:363–8. PubMed https://doi.org/10.1093/cid/cir410

95. Qin C, Zhou L, Hu Z, Zhang S, Yang S, Tao Y, et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin Infect Dis. 2020;71:762–8. PubMed https://doi.org/10.1093/cid/ciaa248

96. Beaman L, Benjamini E, Pappagianis D. Activation of macrophages by lymphokines: enhancement of phagosome-lysosome fusion and killing of *Coccidioides immitis.* Infect Immun. 1983;39:1201–7. PubMed https://doi.org/10.1128/IAI.39.3.1201-1207.1983

97. The RECOVERY Collaborative Group. Dexamethasone in hospitalized patients with Covid-19—preliminary report. N Engl J Med. 2021;384:693–704. PubMed https://doi.org/10.1056/NEJMoa2021436

98. Galgiani JN, Ampel NM, Blair JE, Catanzaro A, Geertsma F, Hoover SE, et al. 2016 Infectious Diseases Society of America (IDSA) clinical practice guideline for the treatment of coccidioidomycosis. Clin Infect Dis. 2016;63:e112–46. PubMed https://doi.org/10.1093/cid/ciw360

99. Centers for Disease Control and Prevention. Recommendation regarding the use of cloth face coverings, especially in areas of significant community-based transmission. 2020 [cited 2020 Aug 18]. https://www.cdc.gov/coronavirus/2019-ncov/prevent-getting-sick/cloth-face-cover.html

100. Akram SM, Koirala J. Coccidioidomycosis. 2020 [cited 2020 May 28]. https://www.ncbi.nlm.nih.gov/books/NBK448161/

101. Konda A, Prakash A, Moss GA, Schmoldt M, Grant GD, Guha S. Aerosol filtration efficiency of common fabrics used in respiratory cloth masks. ACS Nano. 2020;14:6339–47. PubMed https://doi.org/10.1021/acsnano.0c03252

102. McCullough NV, Brosseau LM, Vesley D. Collection of three bacterial aerosols by respiratory and surgical mask filters under varying conditions of flow and relative humidity. Ann Occup Hyg. 1997;41:677–90. PubMed https://doi.org/10.1016/S0003-4878(97)00022-7

103. State of California Department of Industrial Relations. Protection from valley fever. 2017 [cited 2020 May 28]. https://www.dir.ca.gov/dosh/valley-fever-home.html

104. Shaman J, Kohn M. Absolute humidity modulates influenza survival, transmission, and seasonality. Proc Natl Acad Sci U S A. 2009;106:3243–8. PubMed https://doi.org/10.1073/pnas.0806852106

105. Lowen AC, Steel J. Roles of humidity and temperature in shaping influenza seasonality. J Virol. 2014;88:7692–5. PubMed https://doi.org/10.1128/JVI.03544-13

106. Lowen AC, Mubareka S, Steel J, Palese P. Influenza virus transmission is dependent on relative humidity and temperature. PLoS Pathog. 2007;3:1470–6. PubMed https://doi.org/10.1371/journal.ppat.0030151

107. Shaman J, Pitzer VE, Viboud C, Grenfell BT, Lipsitch M. Absolute humidity and the seasonal onset of influenza in the continental United States [Erratum in: PLoS Biol. 2010;8:10.1371/annotation/35686514-b7a9-4f65-9663-7baefc0d63c0]. PLoS Biol. 2010;8:e1000316. PubMed https://doi.org/10.1371/journal.pbio.1000316

108. Baker RE, Mahmud AS, Wagner CE, Yang W, Pitzer VE, Viboud C, et al. Epidemic dynamics of respiratory syncytial virus in current and future climates. Nat Commun. 2019;10:5512. PubMed https://doi.org/10.1038/s41467-019-13562-y

109. Pitzer VE, Viboud C, Alonso WJ, Wilcox T, Metcalf CJ, Steiner CA, et al. Environmental drivers of the spatiotemporal dynamics of respiratory syncytial virus in the United States. PLoS Pathog. 2015;11:e1004591. PubMed https://doi.org/10.1371/journal.ppat.1004591

110. Martinez ME. The calendar of epidemics: seasonal cycles of infectious diseases. PLoS Pathog. 2018;14:e1007327. PubMed https://doi.org/10.1371/journal.ppat.1007327

111. Wang J, Tang K, Feng K, Lv W. Impact of temperature and relative humidity on the transmission of COVID-19: a modeling study in China and the United States. SSRN Electron J. 2020. https://dx.doi.org/10.2139/ssrn.3551767

112. Sajadi MM, Habibzadeh P, Vintzileos A, Shokouhi S, Miralles-Wilhelm F, Amoroso A. Temperature, humidity, and latitude analysis to estimate potential spread and seasonality of coronavirus disease 2019 (COVID-19). JAMA Netw Open. 2020;3:e2011834. PubMed https://doi.org/10.1001/jamanetworkopen.2020.11834

113. Ma Y, Zhao Y, Liu J, He X, Wang B, Fu S, et al. Effects of temperature variation and humidity on the death of COVID-19 in Wuhan, China. Sci Total Environ. 2020;724:138226. PubMed https://doi.org/10.1016/j.scitotenv.2020.138226

114. Baker RE, Yang W, Vecchi GA, Metcalf CJE, Grenfell BT. Susceptible supply limits the role of climate in the early SARS-CoV-2 pandemic. Science. 2020;369:315–9. PubMed https://doi.org/10.1126/science.abc2535

115. Csavina J, Field J, Félix O, Corral-Avitia AY, Sáez AE, Betterton EA. Effect of wind speed and relative humidity on atmospheric dust concentrations in semi-arid climates. Sci Total Environ. 2014;487:82–90. PubMed https://doi.org/10.1016/j.scitotenv.2014.03.138

116. Olson DR, Huynh M, Fine A, Baumgartner J, Castro A, Chan HT, et al.; New York City Department of Health and Mental Hygiene COVID-19 Response Team. Preliminary estimate of excess mortality during the COVID-19 outbreak—New York City, March 11–May 2, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:603–5. PubMed https://doi.org/10.15585/mmwr.mm6919e5

117. Frank AL, Liebman AK, Ryder B, Weir M, Arcury TA. Health care access and health care workforce for immigrant workers in the agriculture, forestry, and fisheries sector in the southeastern US. Am J Ind Med. 2013;56:960–74. PubMed https://doi.org/10.1002/ajim.22183

118. McCurdy SA, Portillo-Silva C, Sipan CL, Bang H, Emery KW. Risk for coccidioidomycosis among Hispanic farm workers, California, USA, 2018. Emerg Infect Dis. 2020;26:1430–7. PubMed https://doi.org/10.3201/eid2607.200024

119. State of California. Essential workforce. 2020 [cited 2020 May 15]. https://covid19.ca.gov/essential-workforce/

120. Koh D. Occupational risks for COVID-19 infection. Occup Med (Lond). 2020;70:3–5. PubMed https://doi.org/10.1093/occmed/kqaa036

121. Baker MG, Peckham TK, Seixas NS. Estimating the burden of United States workers exposed to infection or disease: a key factor in containing risk of COVID-19 infection. PLoS One. 2020;15:e0232452. PubMed https://doi.org/10.1371/journal.pone.0232452

122. Brown S, Brooks R, Dong XS. Coronavirus and health disparities in construction. The Center for Construction Research and Training. 2020 [cited 2020 Oct 16]. https://www.cpwr.com/wp-content/uploads/publications/DataBulletin-May2020.pdf

123. Brown J. Coronavirus has struck construction sites across Colorado, including a school and off-campus housing project. The Colorado Sun. 2020 [cited 2020 Oct 16]. https://coloradosun.com/2020/07/24/coronavirus-at-construction-sites/

124. Reed J. "Significant outbreak" of COVID-19 among construction workers at Alabama's Bryant-Denny Stadium. MSN. 2020 [cited 2020 Oct 16]. https://www.msn.com/en-us/sports/ncaafb/significant-outbreak-of-covid-19-among-construction-workers-at-alabamas-bryant-denny-stadium/ar-BB14ntGN

125. Rischar H. COVID-19 outbreak among construction workers may delay opening of new SLC. Construction & Demolition Recycling. 2020 [cited 2020 Oct 16]. https://www.cdrecycler.com/article/covid-19-outbreak-construction-workers-delay-opening-slc/

126. Santa Clara County Public Health. COVID-19 cases at construction sites highlight need for continued vigilance in sectors that have reopened. 2020 [cited 2020 Oct 16]. https://www.sccgov.org/sites/covid19/Pages/press-release-06-12-2020-cases-at-construction-sites.aspx

127. Centers for Disease Control and Prevention. Communities, schools, workplaces, and events. 2020 [cited 2020 Oct 16]. https://www.cdc.gov/coronavirus/2019-ncov/community/guidance-agricultural-workers.html

128. Arcury TA, Weir M, Chen H, Summers P, Pelletier LE, Galván L, et al. Migrant farmworker housing regulation violations in North Carolina. Am J Ind Med. 2012;55:191–204. PubMed https://doi.org/10.1002/ajim.22011

129. Quandt SA, Brooke C, Fagan K, Howe A, Thornburg TK, McCurdy SA. Farmworker housing in the United States and its impact on health. New Solut. 2015;25:263–86. PubMed https://doi.org/10.1177/1048291115601053

130. Lusk J. Purdue food and agriculture vulnerability index. Purdue University. 2020 [cited 2020 Oct 16]. https://ag.purdue.edu:443/agecon/Pages/FoodandAgVulnerabilityIndex.aspx?_ga=2.49471334.1159720487.1600111458-250602208.1598985334

131. National Center for Farmworker Health, Inc. COVID-19 in rural America: impact on farms and agricultural workers. 2020 Oct [cited 2020 Oct 16]. http://www.ncfh.org/msaws-and-covid-19.html

132. Lauten-Scrivner A. Foster farms COVID-19 deaths among worst work-related outbreaks in California, official says. Merced Sun-Star. 2020 Sep 16 [cited 2020 Oct 16]. https://www.mercedsunstar.com/news/coronavirus/article245767575.html

133. Botts J, Cimini K. Investigation: COVID rips through motel rooms of guest workers who pick nation's produce. CalMatters. 2020 [cited 2020 Oct 16]. https://calmatters.org/california-divide/2020/08/guest-worker-covid-outbreak-california/

134. de los Santos S. Several employees test positive for COVID-19 at produce packing site in Santa Paula. NewsChannel 3–12. 2020 May 14 [cited 2020 Oct 16]. https://keyt.com/health/coronavirus/2020/05/13/employee-tests-positive-for-covid-19-at-produce-packing-site-in-santa-paula/

135. Rode E. Farmworker housing outbreak: 154 workers released from isolation Tuesday. Ventura County Star. 2020 Jul 7 [cited 2020 Oct 16]. https://www.vcstar.com/story/news/local/2020/07/07/oxnard-farmworker-housing-covid-outbreak-coronavirus-recovery-rate/5387928002/

136. Walljasper C, Rosenberg M, Cooke K. Coronavirus spreads among fruit and vegetable packers, worrying U.S. officials. Reuters. 2020 [cited 2020 Oct 16]. https://www.reuters.com/article/us-health-coronavirus-usa-farmworkers-idUSKBN23I1FO

137. Simpson PL, Simpson M, Adily A, Grant L, Butler T. Prison cell spatial density and infectious and communicable diseases: a systematic review [Erratum in: BMJ Open. 2020;10: e026806corr1]. BMJ Open. 2019;9:e026806. PubMed https://doi.org/10.1136/bmjopen-2018-026806

138. Dolan K, Wirtz AL, Moazen B, Ndeffo-Mbah M, Galvani A, Kinner SA, et al. Global burden of HIV, viral hepatitis, and tuberculosis in prisoners and detainees. Lancet. 2016;388:1089–102. PubMed https://doi.org/10.1016/S0140-6736(16)30466-4

139. Stanley LL. Influenza at San Quentin Prison, California. Public Health Rep 1896–1970. 1919;34:996. https://www.jstor.org/stable/pdf/4575142.pdf

140. Besney J, Moreau D, Jacobs A, Woods D, Pyne D, Joffe AM, et al. Influenza outbreak in a Canadian correctional facility. J Infect Prev. 2017;18:193–8. PubMed https://doi.org/10.1177/1757177416689725

141. Finnie TJR, Copley VR, Hall IM, Leach S. An analysis of influenza outbreaks in institutions and enclosed societies. Epidemiol Infect. 2014;142:107–13. PubMed https://doi.org/10.1017/S0950268813000733

142. Akiyama MJ, Spaulding AC, Rich JD. Flattening the curve for incarcerated populations—Covid-19 in jails and prisons. N Engl J Med. N Engl J Med. 2020;2005687.

143. Kinner SA, Young JT, Snow K, Southalan L, Lopez-Acuña D, Ferreira-Borges C, et al. Prisons and custodial settings are part of a comprehensive response to COVID-19. Lancet Public Health. 2020;5:e188–9. PubMed https://doi.org/10.1016/S2468-2667(20)30058-X

144. Wallace M, Hagan L, Curran KG, Williams SP, Handanagic S, Bjork A, et al. COVID-19 in correctional and detention facilities—United States, February–April 2020. MMWR Morb Mortal Wkly Rep. 2020;69:587–90. PubMed https://doi.org/10.15585/mmwr.mm6919e1

145. California Department of Corrections and Rehabilitation. Population COVID-19 tracking. 2020 [cited 2020 Aug 6]. https://www.cdcr.ca.gov/covid19/population-status-tracking/

146. Correctional Health Services and Department of Correction. Board of Correction daily Covid-19 update. 2020 [cited 2020 May 21]. https://www1.nyc.gov/assets/boc/downloads/pdf/News/covid-19/Public_Reports/Board%20of%20Correction%20Daily%20Public%20Report_5_14_2020.pdf

147. The New York Times. Coronavirus in the U.S.: latest map and case count. 2020 [cited 2020 May 28]. https://www.nytimes.com/interactive/2020/us/coronavirus-us-cases.html?auth=login-email&login=email

148. Ohio Department of Rehabilitation & Correction. COVID-19 inmate testing. 2020 [cited 2020 May 21]. https://drc.ohio.gov/Portals/0/DRC%20COVID-19%20Information%2004-19-2020%20%201305.pdf

149. Sabalow R, Pohl J. California severely short on firefighting crews after COVID-19 lockdown at prison camps. The Sacramento Bee. 2020 [cited 2020 Aug 18]. https://www.sacbee.com/news/california/fires/article243977827.html

150. Freedman M, Jackson BR, McCotter O, Benedict K. Coccidioidomycosis outbreaks, United States and worldwide, 1940–2015. Emerg Infect Dis. 2018;24:417–23. PubMed https://doi.org/10.3201/eid2403.170623

151. MacLean M. Epidemiology of coccidioidomycosis—15 California counties, 2007–2011. 2014 [cited 2020 May 28]. https://www.vfce.arizona.edu/sites/vfce/files/the_epidemiology_of_coccidioidomycosis_collaborative_county_report.pdf

152. Prison Law Office. Valley fever and CDCR housing. 2019 [cited 2020 May 28]. https://prisonlaw.com/wp-content/uploads/2019/04/Valley-Fever-info-April-2019.pdf

153. Dubey T. Increased cases of valley fever disease in central California: an update. In: Razzaghi-Abyaneh M, Shams-Ghahfarokhi M, and Rai M, editors. Medical mycology: current trends and future prospects. Boca Raton (FL): CRC Press; 2015. p. 274–88.

154. Lee LA, Yuan J, Vugia D, Wheeler C, Chapnick R, Mohle-Boetani J. Increased coccidioidomycosis among inmates at a California prison. J Correct Health Care. 2017;23:347–52. PubMed https://doi.org/10.1177/1078345817716451

155. Ciencewicki J, Jaspers I. Air pollution and respiratory viral infection. Inhal Toxicol. 2007;19:1135–46. PubMed https://doi.org/10.1080/08958370701665434

156. Cui Y, Zhang ZF, Froines J, Zhao J, Wang H, Yu SZ, et al. Air pollution and case fatality of SARS in the People's Republic of China: an ecologic study. Environ Health. 2003;2:15. PubMed https://doi.org/10.1186/1476-069X-2-15

157. Becker S, Soukup JM. Exposure to urban air particulates alters the macrophage-mediated inflammatory response to respiratory viral infection. J Toxicol Environ Health A. 1999;57:445–57. PubMed https://doi.org/10.1080/009841099157539

158. Kaan PM, Hegele RG. Interaction between respiratory syncytial virus and particulate matter in guinea pig alveolar macrophages. Am J Respir Cell Mol Biol. 2003;28:697–704. PubMed https://doi.org/10.1165/rcmb.2002-0115OC

159. Zanobetti A, Schwartz J. Are diabetics more susceptible to the health effects of airborne particles? Am J Respir Crit Care Med. 2001;164:831–3. PubMed https://doi.org/10.1164/ajrccm.164.5.2012039

160. Brandt EB, Beck AF, Mersha TB. Air pollution, racial disparities, and COVID-19 mortality. J Allergy Clin Immunol. 2020;146:61–3. PubMed https://doi.org/10.1016/j.jaci.2020.04.035

161. Wu X, Nethery RC, Sabath BM, Braun D, Dominici F. Air pollution and COVID-19 mortality in the United States: strengths and limitations of an ecological regression analysis. Science Advances; 2020;6:eabd4049. PubMed https://doi.org/10.1126/sciadv.abd4049

162. Zhu Y, Xie J, Huang F, Cao L. Association between short-term exposure to air pollution and COVID-19 infection: evidence from China. Sci Total Environ. 2020;727:138704. PubMed https://doi.org/10.1016/j.scitotenv.2020.138704

163. Fattorini D, Regoli F. Role of the chronic air pollution levels in the Covid-19 outbreak risk in Italy. Environ Pollut. 2020;264:114732. PubMed https://doi.org/10.1016/j.envpol.2020.114732

164. Malo J, Holbrook E, Zangeneh T, Strawter C, Oren E, Robey I, et al. Enhanced antibody detection and diagnosis of coccidioidomycosis with the MiraVista IgG and IgM detection enzyme immunoassay. J Clin Microbiol. 2017;55:893–901. PubMed https://doi.org/10.1128/JCM.01880-16

165. Kassis C, Durkin M, Holbrook E, Myers R, Wheat L. Advances in diagnosis of progressive pulmonary and disseminated coccidioidomycosis. Clin Infect Dis. 2020;ciaa188. PubMed https://doi.org/10.1093/cid/ciaa188

166. Dizon D, Mitchell M, Dizon B, Libke R, Peterson MW. The utility of real-time polymerase chain reaction in detecting *Coccidioides immitis* among clinical specimens in the Central California San Joaquin Valley. Med Mycol. 2019;57:688–93. PubMed https://doi.org/10.1093/mmy/myy111

167. Blair JE, Coakley B, Santelli AC, Hentz JG, Wengenack NL. Serologic testing for symptomatic coccidioidomycosis in immunocompetent and immunosuppressed hosts. Mycopathologia. 2006;162:317–24. PubMed https://doi.org/10.1007/s11046-006-0062-5

168. Khan S, Saubolle MA, Oubsuntia T, Heidari A, Barbian K, Goodin K, et al. Interlaboratory agreement of coccidioidomycosis enzyme immunoassay from two different manufacturers. Med Mycol. 2019;57:441–6. PubMed https://doi.org/10.1093/mmy/myy059

169. Saubolle MA. Laboratory aspects in the diagnosis of coccidioidomycosis. Ann N Y Acad Sci. 2007;1111:301–14. PubMed https://doi.org/10.1196/annals.1406.049

170. Valley Fever Center for Excellence. Valley fever (coccidioidomycosis): tutorial for primary care professionals. 2016 [cited 2020 May 22]. https://vfce.arizona.edu/sites/vfce/files/tutorial_for_primary_care_professionals.pdf

171. APM Research Lab. COVID-19 deaths analyzed by race and ethnicity. 2020 [cited 2020 Aug 18]. https://www.apmresearchlab.org/covid/deaths-by-race

172. Kim JM, Chung YS, Jo HJ, Lee NJ, Kim MS, Woo SH, et al. Identification of coronavirus isolated from a patient in Korea with COVID-19. Osong Public Health Res Perspect. 2020;11:3–7. PubMed https://doi.org/10.24171/j.phrp.2020.11.1.02

173. He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral shedding and transmissibility of COVID-19 [Erratum in: Nat Med. 2020;26:1491–3]. Nat Med. 2020;26:672–5. PubMed https://doi.org/10.1038/s41591-020-0869-5

174. Goldberg MH, Gustafson A, Maibach EW, Ballew MT, Bergquist P, Kotcher JE X, et al. Mask-wearing increased after a government recommendation: a natural experiment in the U.S. during the COVID-19 pandemic. Front. Commun. 2020;5:44. https://doi.org/10.3389/fcomm.2020.00044